ReviewInternational journal of molecular sciences2019
Potential Fluid Biomarkers for the Diagnosis of Mild Cognitive Impairment.
Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- N-3 Polyunsaturated Fatty Acids in Elderly with Mild Cognitive Impairment: A Systemic Review and Meta-Analysis.Journal of Alzheimer's disease : JAD · 2024Pooled it
- The prevalence of mild cognitive impairment in Latin America and the Caribbean: a systematic review and meta-analysis.Aging & mental health · 2022Pooled it
- Systematic Review on the Potential Effect of Berry Intake in the Cognitive Functions of Healthy People.Nutrients · 2022Pooled it
- Convergent Functional Changes of Default Mode Network in Mild Cognitive Impairment Using Activation Likelihood Estimation.Frontiers in aging neuroscience · 2021Pooled it
- Circulating MicroRNAs as Diagnostic Biomarkers of Clinical Cognitive Impairment: A Meta-Analysis.American journal of Alzheimer's disease and other dementiasPooled it
- Generalizability of blood-based biomarkers of Alzheimer's disease and related dementias in a multicultural cohort of older adults: The effect of adjustment for kidney function.Journal of Alzheimer's disease : JAD · 2026Article
- Structural and functional brain alterations in depression with Alzheimer's disease and mild cognitive impairment: a multimodal coordinate-based meta-analysis.Frontiers in aging neuroscience · 2026Review
- Plasma senescence associated secretory proteins: A new link to mild cognitive impairment.The journal of nutrition, health & aging · 2025Article
- Enhanced associations between subjective cognitive concerns and blood-based AD biomarkers using a novel EMA approach.Alzheimer's research & therapy · 2025Article
- Serum and Cerebrospinal Fluid Malondialdehyde Levels in Patients with Mild Cognitive Impairment.Journal of xenobiotics · 2025Article
- Growth-associated protein 43 is associated with faster functional decline among amyloid-positive individuals with objectively defined subtle cognitive decline and mild cognitive impairment.Neuropsychology · 2025Article
- Article
- The role of serum biomarkers in the decline of cognitive function in hemodialysis patients: a single-center retrospective study.Frontiers in medicine · 2025Article
- Comparing the predictive validity of four MCI definitions for incident dementia in demographically diverse community-dwelling individuals: Results from the Einstein Aging Study (EAS).Journal of the International Neuropsychological Society : JINS · 2025Article
- Effect of a specific food intervention with Tamogitake mushroom, Moringa leaves, or rice bran on intestinal microbiota and cognitive function in elderly Japanese.Frontiers in nutrition · 2025Article
- The impact of living environmental factors on cognitive function and mild cognitive impairment: evidence from the Chinese elderly population.BMC public health · 2024Article
- Differential expression of N-glycopeptides derived from serum glycoproteins in mild cognitive impairment (MCI) patients.Proteomics · 2024Article
- Association of Serum Extracellular Vesicle miRNAs with Cognitive Functioning and Quality of Life in Parkinson's Disease.Biomolecules · 2024Article
- Machine Learning Classification of Patients with Amnestic Mild Cognitive Impairment and Non-Amnestic Mild Cognitive Impairment from Written Picture Description Tasks.Brain sciences · 2024Article
- Specific Binding of Alzheimer's Aβ Peptides to Extracellular Vesicles.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mild cognitive impairment (MCI) is characterized by a level of cognitive impairment that is lower than normal for a person's age, but a higher function than that that observed in a demented person. MCI represents a transitional state between normal aging and dementia disorders, especially Alzheimer's disease (AD). Much effort has been made towards determining the prognosis of a person with MCI who will convert to AD. It is now clear that cerebrospinal fluid (CSF) levels of Aβ40, Aβ42, total tau and phosphorylated tau are useful for predicting the risk of progression from MCI to AD. This review highlights the advantages of the current blood-based biomarkers in MCI, and discusses some of these challenges, with an emphasis on recent studies to provide an overview of the current state of MCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.